CLINICAL TRIALS PROFILE FOR AMISULPRIDE
✉ Email this page to a colleague
All Clinical Trials for amisulpride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00126009 ↗ | SOLMANIA - Comparison of Valproate-Amisulpride and Valproate-Haloperidol in Bipolar I Patients | Completed | Sanofi | Phase 2 | 2004-05-01 | The primary objective is: - To compare the efficacy of the association valproate-amisulpride (400 to 800 mg/day) to the association valproate-haloperidol (5 to 15 mg/day) in bipolar I patients suffering from a manic episode according to DSM IV TR (American Psychiatric Association [APA] 2000) and treated for a 3-month period. The secondary objectives are: - To evaluate the clinical and biological safety of the association valproate-amisulpride to the association valproate-haloperidol; - To assess the patient status 3 weeks and 3 months after inclusion; and - To assess patient satisfaction at 3 months. |
| NCT00204061 ↗ | Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis | Completed | Department of Psychiatry University of Bonn | Phase 4 | 2001-01-01 | The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment. |
| NCT00204061 ↗ | Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis | Completed | German Federal Ministry of Education and Research | Phase 4 | 2001-01-01 | The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment. |
| NCT00204061 ↗ | Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis | Completed | German Research Network On Schizophrenia | Phase 4 | 2001-01-01 | The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment. |
| NCT00204061 ↗ | Early Pharmacological and Psychological Intervention for Late Prodromal States of Psychosis | Completed | Heinrich-Heine University, Duesseldorf | Phase 4 | 2001-01-01 | The study will provide an empirical basis for a pharmacological treatment option. An open-label, randomized, multi-centre parallel group design is used. An intensified clinical management (CM), which allows needs-based psychological crisis intervention, is compared to a combination of such a CM and the atypical neuroleptic amisulpride. The central hypothesis is that the combination of a clinical management with an atypical neuroleptic is the superior treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for amisulpride
Condition Name
Clinical Trial Locations for amisulpride
Trials by Country
Clinical Trial Progress for amisulpride
Clinical Trial Phase
Clinical Trial Sponsors for amisulpride
Sponsor Name
